Skip to content

Study · Animal study (in vivo) · mouse · 2023

2 results

Immunological effects of heated intraperitoneal chemotherapy can be augmented by thymosin α1.

Nevo N, Lee Goldstein A, Bar-David S, Abu-Abeid A, Dayan D, Lahat G, Nizri E

International immunopharmacology7 Feb 2023Cited by 7 (Europe PMC)

PMID36758296 (opens in a new tab)DOI10.1016/j.intimp.2023.109829 (opens in a new tab)PepBankPUB-36758296
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with peritoneal metastases of colorectal carcinoma, overall survival in Tα1-treated mice was longer than in HIPEC-treated mice.

    In plain wordsIn mice with colorectal cancer spread, mice given thymosin alpha‑1 lived longer than mice given heated chemotherapy only.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseOverall survival
    Study

    mousen: not reported in source

    Murine peritoneal metastases of colorectal carcinoma with mitomycin-based HIPEC
    Comparator
    HIPEC-treated mice
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Measurements

    Overall survival
    16.3 days
    Tα1-treated
    Overall survival
    14.1 days
    HIPEC-treated

    Source sentences

    Summary
    The OS of Tα1 treated mice significantly improved compared to HIPEC-treated mice (16.3 ± 0.8 vs 14.1 ± 0.6 days, respectively, P = 0.02)
    1 context sentence
    Summary · context
    We used an experimental murine model of PM-CRC combined with mitomycin (MMC)-based HIPEC.

Studies that did not test the peptide alone1

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In mice with peritoneal metastases of colorectal carcinoma, overall survival in the Tα1-treated group (tested as an add-on to HIPEC) was longer than in sham-treated mice.

    In plain wordsIn mice with colorectal cancer spread, the group given thymosin alpha‑1 with heated chemotherapy lived longer than sham-treated mice.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseOverall survival
    Study

    mousen: not reported in source

    Murine peritoneal metastases of colorectal carcinoma with mitomycin-based HIPEC
    Comparator
    Sham-treated mice
    Outcome group
    Mortality · Cancer

    Measurements

    Overall survival
    16.3 days
    Tα1-treated
    Overall survival
    11.8 days
    sham

    Source sentences

    Summary
    The OS of Tα1 treated mice significantly improved compared to HIPEC-treated mice (16.3 ± 0.8 vs 14.1 ± 0.6 days, respectively, P = 0.02) and vs sham (11.8 ± 0.8 days, P = 0.007).
    1 context sentence
    Summary · context
    We used an experimental murine model of PM-CRC combined with mitomycin (MMC)-based HIPEC.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.